Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Andrew David Zelenetz, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Huda S. Salman, Jacob D. Soumerai, Vaishalee Padgaonkar Kenkre, Adam Steven Asch, Judith Llorin-Sangalang, Joanne Li, Igor Gorbatchevsky, John M. Pagel
Title Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.
Journal
Vol
Issue
Date
URL https://meetinglibrary.asco.org/record/186023/abstract
Abstract Text J Clin Oncol 38: 2020 (suppl; abstr 8016), DOI: 10.1200/JCO.2020.38.15_suppl.8016

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown marginal zone B-cell lymphoma not applicable ME-401 Phase I Actionable In a Phase I trial, ME-401 treatment was well-tolerated, resulted in an objective response rate of 100% (4/4) in patients with relapsed or refractory marginal zone B-cell lymphoma (J Clin Oncol 38: 2020 (suppl; abstr 8016); NCT02914938). detail...
Unknown unknown diffuse large B-cell lymphoma not applicable ME-401 Phase I Actionable In a Phase I trial, ME-401 treatment was well-tolerated, resulted in an objective response rate of 25% (2/8) in patients with relapsed or refractory diffuse large B-cell lymphoma (J Clin Oncol 38: 2020 (suppl; abstr 8016); NCT02914938). detail...
Unknown unknown follicular lymphoma not applicable ME-401 Phase I Actionable In a Phase I trial, ME-401 treatment was well-tolerated, resulted in an objective response rate of 83% (29/35) in patients with relapsed or refractory follicular lymphoma (J Clin Oncol 38: 2020 (suppl; abstr 8016); NCT02914938). detail...
Unknown unknown CLL/SLL not applicable ME-401 Phase I Actionable In a Phase I trial, ME-401 treatment was well-tolerated, resulted in an objective response rate of 89% (9/10) in patients with relapsed or refractory CLL/SLL (J Clin Oncol 38: 2020 (suppl; abstr 8016); NCT02914938). detail...